

SUPPLEMENTARY TABLE S2. ESTIMATES OF THE CUMULATIVE PROBABILITY OF REMAINING VIROLOGICALLY SUPPRESSED AFTER INITIATING ANTIRETROVIRAL THERAPY OR SWITCHING TO A SECOND- OR THIRD-LINE ANTIRETROVIRAL THERAPY AMONG PATIENTS PARTICIPATING TO THE PAN-AFRICAN STUDIES TO EVALUATE RESISTANCE COHORT 2007–2015

<i>No. of months</i>	<i>No. of virological failures<sup>a</sup></i>	<i>Probability of remaining suppressed (95% CI)</i>
After initiating first- or second-line ART ( <i>n</i> = 2,420 patients with $\geq 2$ sVL results)		
12	81	0.97 (0.96–0.97)
24	269	0.88 (0.87–0.90)
36	348	0.83 (0.81–0.84)
48	370	0.80 (0.78–0.82)
60	396	0.78 (0.75–0.80)
72	414	0.74 (0.72–0.77)
After switch to second- or third-line ART ( <i>n</i> = 149 switches)		
12	8	0.92 (0.84–0.96)
24	17	0.79 (0.69–0.87)
36	20	0.73 (0.60–0.82)
48	23	0.60 (0.42–0.74)
60	24	0.53 (0.33–0.70)
After initiating first- or second-line ART for those with no change in regimen ( <i>n</i> = 2,271 patients)		
12	42	0.98 (0.97–0.99)
24	179	0.92 (0.90–0.93)
36	244	0.87 (0.85–0.88)
48	264	0.84 (0.83–0.86)
60	282	0.82 (0.80–0.84)
72	299	0.79 (0.77–0.82)

<sup>a</sup>As defined by study VL. ART, antiretroviral therapy; CI, confidence interval; sVL, study viral load.

SUPPLEMENTARY TABLE S3. CUMULATIVE ACQUIRED HIV DRUG RESISTANCE AFTER INITIATING ANTIRETROVIRAL THERAPY, BY FOLLOW-UP TIME AMONG PATIENTS PARTICIPATING TO THE PAN-AFRICAN STUDIES TO EVALUATE RESISTANCE COHORT 2007–2015

	<i>Patients with <math>\geq 2</math> consecutive sVL results (N = 2,420)</i>		
	<i>Total<sup>b</sup></i>	<i>n (%)</i>	<i>No VL data</i>
HIV drug resistance <sup>a</sup> (NRTI, NNRTI, or PI)			
0–1 years	2,420	54 (2.2)	0
1–2 years	2,313	139 (6.0)	107
2–3 years	1,638	129 (7.9)	782
3–4 years	883	83 (9.4)	1,537
4–5 years	818	86 (10.5)	1,602
>5 years	579	72 (12.4)	1,841
NRTI drug resistance			
0–1 years	2,420	49 (2.0)	0
1–2 years	2,313	118 (5.1)	107
2–3 years	1,638	110 (6.7)	782
3–4 years	883	74 (8.4)	1,537
4–5 years	818	76 (9.3)	1,602
>5 years	579	64 (11.1)	1,841
NNRTI drug resistance			
0–1 years	2,420	51 (2.1)	0
1–2 years	2,313	131 (5.7)	107
2–3 years	1,638	124 (7.6)	782
3–4 years	883	77 (8.7)	1,537
4–5 years	818	83 (10.1)	1,602
>5 years	579	69 (11.9)	1,841
PI drug resistance			
0–1 years	2,420	1 (0.04)	0
1–2 years	2,313	5 (0.2)	107
2–3 years	1,638	6 (0.4)	782
3–4 years	883	5 (0.6)	1,537
4–5 years	818	4 (0.5)	1,602
>5 years	579	3 (0.5)	1,841

*Italic* figures represent the number of participants for whom no sVL data were available and whom were not included in the analysis.

<sup>a</sup>As defined by a study HIVDR genotyping results.

<sup>b</sup>Number of patients still in follow-up with at least two consecutive sVL results.

HIVDR, HIV drug resistance; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.